Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in First-Line Carcinoma of Unknown Primary
NCT00360360Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jul 2006
- Primary completion
- Feb 2008
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, erlotinib in carcinoma of unknown primary (CUP), sponsored by SCRI Development Innovations. Started Jul 2006; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
carcinoma of unknown primary (CUP)
Beyond the preview
Go deeper on NCT00360360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00360360.